Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs BCT 100 (Primary)
- Indications Adenocarcinoma; Liver cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bio-Cancer Treatment International
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
- 27 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated